Paper Details

  1. Home
  2. Paper Details

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

Author: , BadeschD B, BarstR J, BlackburnS D, BourgeR C, BrundageB H, ClaytonL M, CrowJ W, GrovesB M, JöbsisM M, KellerC A, KoernerS K, LanglebenD, LongW A, McGoonM D, MuraliS, RichS, RubinL J, ShortinoD, TapsonV F, UretskyB F

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Continuous intravenous infusion of epoprostenol plus conventional therapy improved exercise capacity, quality of life, hemodynamics, and survival in patients with severe primary pulmonary hypertension compared to conventional therapy alone.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Primary pulmonary hypertension is a progressive disease for which no treatment has been shown in a prospective, randomized trial to improve survival. METHODS: We conducted a 12-week prospective, randomized, multicenter open trial comparing the effects of the continuous intravenous infus...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJM199602013340504

データ提供：米国国立医学図書館（NLM）

Epoprostenol for Primary Pulmonary Hypertension: A Promising Treatment

This research delves into the world of [cardiology], focusing on the serious condition of primary pulmonary hypertension. The study investigates the effectiveness of continuous intravenous infusion of epoprostenol, a drug that dilates blood vessels, in treating this life-threatening disease. It's like seeking a solution to a desert storm that threatens to choke off vital resources.

The authors conducted a [prospective, randomized, multicenter open trial] comparing the effects of epoprostenol plus conventional therapy to conventional therapy alone in 81 patients with severe primary pulmonary hypertension. This study is like conducting a scientific expedition in search of a remedy for a debilitating condition.

The study found that epoprostenol significantly improved exercise capacity, quality of life, and hemodynamics in patients with severe primary pulmonary hypertension. It's like discovering a spring in the desert that brings life and energy back to a parched land.

A Beacon of Hope for Pulmonary Hypertension

This research provides a beacon of hope for individuals suffering from primary pulmonary hypertension. The findings suggest that epoprostenol can significantly improve the lives of patients with this serious condition. It's like finding a path through a treacherous desert, leading to improved quality of life and a chance for survival.

Navigating Pulmonary Hypertension

This research highlights the importance of early diagnosis and prompt treatment for primary pulmonary hypertension. It's like recognizing the signs of a looming desert storm and taking action to mitigate its effects.

Dr. Camel's Conclusion

The study underscores the effectiveness of epoprostenol for treating primary pulmonary hypertension, offering a promising approach to managing this challenging condition. It's like discovering a refreshing oasis in a vast and unforgiving desert, providing hope and a path towards improved health.

Date :
  1. Date Completed 1996-02-01
  2. Date Revised 2023-10-24
Further Info :

Pubmed ID

8532025

DOI: Digital Object Identifier

10.1056/NEJM199602013340504

Related Literature

Article Analysis
・Effective treatment of pulmonary hypertension
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.